Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vaccinia virus p37 protein (p37 (F13L))
- Target
- p37 (F13L)
- Molecular classification
- Viral protein
01
Overview
The vaccinia virus p37 protein (F13L, also called VP37) is a viral envelope protein required for the formation and egress of extracellular virus particles in orthopoxvirus infections, including smallpox and monkeypox. Tecovirimat (ST-246) specifically targets the p37 protein, disrupting its interaction with host proteins Rab9 and TIP47, thereby blocking viral envelopment and release from infected cells. This mode of action is highly specific for orthopoxviruses, and tecovirimat is orally bioavailable, with demonstrated efficacy and safety in animal models and human trials. Resistance mutations can occur at the VP37 dimer interface. No notable off-target cytotoxicity has been observed in laboratory studies.
- Other names
- F13L proteinorthopoxvirus VP37 envelope wrapping proteinp37 viral protein
02
Mechanism of action
Inhibition of p37/F13L protein, blocking formation of extracellular enveloped virus particles and preventing viral egress from infected cells
03
Biological functions
Viral envelopmentSecretion of extracellular forms of virusVirus egress
04
Disease associations
Infection (orthopoxvirus diseases including smallpox, monkeypox, cowpox)
05
Safety considerations
Resistance mutations in VP37/F13L, especially during prolonged therapy in immunocompromised individualsPotential for hypoglycemia with coadministration of repaglinideNo significant genotoxicity, bone marrow toxicity, or chromosomal aberrations observed in preclinical studies
06
Interacting drugs
Tecovirimat (ST-246, TPOXX)
Beyond the preview
Go deeper on Vaccinia virus p37 protein (p37 (F13L)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaccinia virus p37 protein (p37 (F13L)).